Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Dec;34(12):2442–2444. doi: 10.1128/aac.34.12.2442

In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin.

D M Yajko 1, C A Sanders 1, P S Nassos 1, W K Hadley 1
PMCID: PMC172081  PMID: 2088204

Abstract

We tested the activity of the new fluoroquinolone sparfloxacin (CI-978; AT 4140) against 30 strains of Mycobacterium avium complex (MAC) isolated from patients with acquired immune deficiency syndrome. MICs of sparfloxacin (range, less than or equal to 0.06 to 4 micrograms/ml) were lower than MICs of ciprofloxacin for all 30 strains, and MBCs for acid-fast bacteria were lower for 28 of the 30 strains. In synergism experiments using 10 strains of MAC, fractional inhibitory concentration indices revealed that the combination of sparfloxacin plus ethambutol was synergistic against 9 strains, and the three-drug combination of sparfloxacin plus ethambutol plus rifampin was synergistic against all strains. In the absence of ethambutol, the combination of sparfloxacin plus rifampin appeared to be antagonistic against three of the MAC strains.

Full text

PDF
2442

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  2. Fenlon C. H., Cynamon M. H. Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare. Antimicrob Agents Chemother. 1986 Mar;29(3):386–388. doi: 10.1128/aac.29.3.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Hallander H. O., Dornbusch K., Gezelius L., Jacobson K., Karlsson I. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob Agents Chemother. 1982 Nov;22(5):743–752. doi: 10.1128/aac.22.5.743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Heifets L. B., Lindholm-Levy P. J. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother. 1990 May;34(5):770–774. doi: 10.1128/aac.34.5.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Naik S. P., Samsonoff W. A., Ruck R. E. Effects of surface-active agents on drug susceptibility levels and ultrastructure of Mycobacterium avium complex organisms isolated from AIDS patients. Diagn Microbiol Infect Dis. 1988 Sep;11(1):11–19. doi: 10.1016/0732-8893(88)90068-5. [DOI] [PubMed] [Google Scholar]
  6. Nakamura S., Kurobe N., Ohue T., Hashimoto M., Shimizu M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother. 1990 Jan;34(1):89–93. doi: 10.1128/aac.34.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Norrby S. R., Jonsson M. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother. 1988 Aug;32(8):1278–1281. doi: 10.1128/aac.32.8.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Wise R., Ashby J. P., Andrews J. M. In vitro activity of PD 127,391, an enhanced-spectrum quinolone. Antimicrob Agents Chemother. 1988 Aug;32(8):1251–1256. doi: 10.1128/aac.32.8.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Yajko D. M., Kirihara J., Sanders C., Nassos P., Hadley W. K. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1988 Sep;32(9):1392–1395. doi: 10.1128/aac.32.9.1392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Yajko D. M., Nassos P. S., Hadley W. K. Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother. 1987 Oct;31(10):1579–1584. doi: 10.1128/aac.31.10.1579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Yajko D. M., Nassos P. S., Hadley W. K. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother. 1987 Jan;31(1):117–120. doi: 10.1128/aac.31.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES